APA

Wagner L. M., Perentesis J. P., Reid J. M., Ames M. M., Safgren S. L., Nelson M. D., Ingle A. M., Blaney S. M. & Adamson P. C. (20100419). Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. : Pediatric blood & cancer.

Chicago

Wagner Lars M, Perentesis John P, Reid Joel M, Ames Matthew M, Safgren Stephanie L, Nelson Marvin D, Ingle Ashish M, Blaney Susan M and Adamson Peter C. 20100419. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. : Pediatric blood & cancer.

Harvard

Wagner L. M., Perentesis J. P., Reid J. M., Ames M. M., Safgren S. L., Nelson M. D., Ingle A. M., Blaney S. M. and Adamson P. C. (20100419). Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. : Pediatric blood & cancer.

MLA

Wagner Lars M, Perentesis John P, Reid Joel M, Ames Matthew M, Safgren Stephanie L, Nelson Marvin D, Ingle Ashish M, Blaney Susan M and Adamson Peter C. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. : Pediatric blood & cancer. 20100419.